

My lab will have a few postdoc openings in the summer of 2021, when a few fellows will be graduating and moving on. Briefly, our lab works on various topics in cancer genomics, metabolism and immunotherapy, collaborating with experimental and clinical labs in the NCI and beyond. Our focus is on developing new analysis approaches for precision oncology that are based on analyzing the tumor transcriptome, both from bulk and from single cell tumor expression data. To study their clinical application, we have recently initiated an effort to comprehensively sequence and analyze many hundreds of patients in our center on an annual basis (including WES, RNAseq and methylome), which we hope may lead to new insights in coming years. Additionally, we have been developing and further studying new approaches for tumor bulk expression deconvolution, cell-specific bacterial identification in the tumor microenvironment and single-cell transcriptomics-based cancer combinatorial target optimization, among others.

Eytan Ruppin, MD, PhD

Cancer Data Science Laboratory

My lab (<https://ccr.cancer.gov/cancer-data-science-laboratory/eytan-ruppin>) is part of the newly formed Cancer Data Science Lab (CDSL, <https://ccr.cancer.gov/cancer-data-science-laboratory>) in NCI's Center for Cancer Research (CCR, <https://ccr.cancer.gov/>), which is the home of about 250 cancer research groups. Almost all CCR labs are experimental or clinical, and quite a few are leaders in various aspects of cancer research. The NIH Bethesda campus, where the CDSL branch is located, is home to the NIH medical center, where many clinical trials of new cancer therapies are carried out.